Julie Megee, a Wrentham resident and breast cancer survivor, will appear on The Balancing Act
airing on Lifetime Television in October, National Breast Cancer Awareness Month. In conjunction with the educational segment about breast cancer, Ms. Megee is sponsoring a fundraiser for
Perceptions Hair Studio
, which she owns and operates in Norton, Mass.
DARA BioSciences, Inc.
Breast cancer survivor from Wrentham, Mass. and Norton, Mass. business owner appears on The Balancing Act airing on Lifetime Television to discuss breast cancer treatment and tamoxifen citrate, Soltamox. (Photo: Business Wire)
(NASDAQ: DARA), a Raleigh, N.C.-based oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, sponsored The Balancing Act
segment. DARA has pledged to match money raised for Breastcancer.org by Ms. Megee.
The segment on The Balancing Act
airs Oct. 14 and 21 at 7 a.m. EDT during Breast Cancer Awareness Month.
Ms. Megee’s breast cancer story is important because it underlies the importance of early diagnosis and treatment options. After discovering a lump in her breast during a self-exam in early 2013, she quickly scheduled a doctor’s appointment, underwent a lumpectomy and radiation therapy, and is now taking Soltamox
(tamoxifen citrate) to prevent recurrence of the disease. Soltamox
is an oral liquid form of the commonly used medication tamoxifen, until recently available in tablet form only.
“I have always had difficulty taking any type of tablet medication, so I asked my oncologist if there was an alternative to the tamoxifen tablet because I couldn’t imagine taking a tablet every day for at least five years,” Ms. Megee said. Her doctor prescribed Soltamox
(tamoxifen citrate) instead, the only liquid formulation of tamoxifen available. DARA BioSciences markets Soltamox
in the United States.
As part of her fundraising effort to support Breastcancer.org, Ms. Megee and her team at Perceptions Hair Studio will donate $5 for every new client appointment. Breastcancer.org is a leading online resource for breast health and breast cancer information. “I am grateful for the opportunity to support Breastcancer.org which does so much to support women with breast cancer like me,” Ms. Megee said. To donate and learn more, visit their
“We are grateful to Julie and her co-workers for supporting our efforts to provide the most reliable, complete and up-to-date information about breast cancer to help women and their loved ones make informed decisions for their lives,” said Rita Lusen, vice president of corporate partnerships and marketing of Breastcancer.org. “Thank you and congratulations to Julie, her team, DARA and The Balancing Act
on producing this timely educational segment about breast cancer and cancer supportive care.”
Ms. Megee joins Nancy Peacock, MD, Tennessee Oncology medical oncologist and breast cancer specialist at St. Thomas Midtown Hospital in Nashville, Tenn., and The Balancing Act
host Danielle Knox in studio and discuss oncology supportive care issues, including the importance of patient compliance to tamoxifen therapy, and how Soltamox
(tamoxifen citrate) oral solution may help improve patient compliance. The segment also touches on side effects of cancer treatment, including skin burns and oral mucositis caused by radiation treatment and chemotherapy. DARA markets
, an oral rinse gel for relief of oral mucositis pain, and
, a topical treatment for skin irritation and burns, in the US oncology/radiology markets. Dr. Peacock and Julie also discuss the important role of patient educational resources such as Breastcancer.org.
“We are pleased to partner with The Balancing Act
to produce this educational segment about breast cancer treatment and support, and appreciate The Balancing Act’s commitment to breast cancer education and programming during Breast Cancer Awareness Month” said
David J. Drutz, MD
, DARA's chief executive officer and chief medical officer. “We are grateful to Dr. Peacock and Ms. Megee for sharing their experiences on national television, so that others may learn from their insights and knowledge.”
According to recently published National Comprehensive Cancer Network (NCCN) Guidelines (Version 3.2013), tamoxifen is the most firmly established adjuvant endocrine therapy for both premenopausal and postmenopausal women with ER-positive breast cancer. Tamoxifen is usually administered as 20mg daily for five years. The American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines published on July 8, 2013, recommends that in women at increased risk of breast cancer age 35 or older, tamoxifen prophylaxis (20mg per day for five years) should be discussed as an option to reduce the risk of estrogen receptor (ER) positive breast cancer. Soltamox
(tamoxifen citrate) oral solution is bioequivalent to tamoxifen and is prescribed for the same indications. Please see Soltamox
Important Safety Information and the Black Box Warning at the end of this press release. For additional information and a copy of the complete Prescribing Information visit
About DARA BioSciences
DARA BioSciences Inc. is an oncology supportive care pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment.